Why some peptides become medicines

Why the same catalog contains approved drugs and research-supply peptides

This catalog contains compounds at very different regulatory positions. Semaglutide and tirzepatide are approved by major regulators worldwide as treatments for type 2 diabetes and obesity. Bremelanotide, tesamorelin, elamipretide, afamelanotide are FDA-approved for narrow indications. Thymosin alpha-1 is approved in 35+ countries but not the US. BPC-157, TB-500, MOTS-c, kisspeptin, DSIP, selank, semax remain in the research-supply category with no approved product anywhere. Understanding the structural factors that determine whether a peptide crosses the regulatory finish line — rather than assuming that approval status reflects biological effectiveness — is essential for reading this catalog critically. Approval status reflects biology plus economics plus regulatory design, and the interaction of those three factors is what produces the observed pattern.

The patent-and-sponsor filter

Drug development is expensive — often over $1 billion in aggregated costs for a phase-3 approval — and that investment has to be recovered through commercial sales. A pharmaceutical company will only take a compound through phase-3 development if it has intellectual property protection that gives it market exclusivity for enough years to recover the investment. Semaglutide and tirzepatide are protected by extensive patent portfolios covering the specific fatty-acid modifications and the specific dual-agonist chemistry. BPC-157 as a sequence is not similarly patentable — the sequence itself is a fragment of a naturally-occurring protein, and no synthetic modifications have been developed that would justify a company investing a billion dollars in the phase-3 program. This is the single largest factor determining which peptides become drugs: not whether they work, but whether they can be protected commercially. Naturally-occurring or minimally-modified sequences with obvious biological relevance are often the least investible from a pharmaceutical company perspective, even when their biology is compelling.

The endpoint-and-indication filter

Regulatory approval requires demonstrating efficacy for a specific indication with a defined endpoint. Compounds that produce large effects on well-established regulatory endpoints (weight loss for obesity, HbA1c for diabetes, hepatic fat for a specific approved-drug population) can be developed straightforwardly because the endpoint is clear and the regulatory pathway is known. Compounds that produce broad or hard-to-quantify effects — general tissue repair, general anti-aging, general wellness — face a much harder regulatory design problem because there is no single approved endpoint that captures what they are supposed to do. BPC-157's mechanistic breadth (tendon, gut, brain, vascular) is scientifically impressive but regulatory-hostile: which indication would you seek approval for, and how would you power a phase-3 trial around it? The peptides that become drugs tend to have narrow, well-defined therapeutic targets. The peptides that stay in the research space tend to have interesting but diffuse profiles that resist packaging as a single regulatory-approvable claim.

The market-size filter

Development economics require enough market size to justify the investment. Obesity affects roughly 40% of American adults; type 2 diabetes affects 13%. These are enormous markets, and the commercial rationale for developing semaglutide and tirzepatide is unambiguous. Rare diseases — Barth syndrome (elamipretide), erythropoietic protoporphyria (afamelanotide), the tesamorelin approved-drug population — have small markets but are supported by specific regulatory incentives (orphan drug designation, priority review) that make development economically viable despite the small patient population. Compounds targeting biology that is common but not clinically defined as a disease (general tissue repair, general longevity) fall between these two categories — no rare-disease incentives and no clear indication that would command insurance reimbursement at drug prices. This economic structure is what channels development toward specific indications and away from broader wellness claims.

What this means for reading the catalog

The practical implication is that the approval status of a peptide does not simply reflect whether it works. It reflects the combination of biological effect plus commercial protectability plus indication clarity plus market size. This is why the strongest human evidence in this catalog concentrates in the metabolic-disease category (large market, clear endpoints, patented compounds) and thins dramatically outside it. It is also why compounds with genuinely interesting biology but structural disincentives for development (unpatentable natural sequences, broad rather than narrow indications) remain in the research-supply space regardless of their scientific interest. Reading each compound page with this framing in mind lets you distinguish 'no approval because the science didn't hold up' (which is rare) from 'no approval because the compound wasn't a good fit for the drug-development apparatus' (which is common). The two conclusions require different responses from an informed reader.

References

• Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2)· Frías JP, Davies MJ, Rosenstock J, et al. · 2021

Links open external, peer-reviewed sources. Healthy Mango does not host trial data.